Copyright
©The Author(s) 2020.
World J Gastroenterol. Oct 21, 2020; 26(39): 5919-5943
Published online Oct 21, 2020. doi: 10.3748/wjg.v26.i39.5919
Published online Oct 21, 2020. doi: 10.3748/wjg.v26.i39.5919
Figure 3 Diagnostic flow-chart to assess liver fibrosis in patients with non-alcoholic fatty liver disease.
NAFLD: Non-alcoholic fatty liver disease; T2DM: Type 2 diabetes mellitus; IR: Insulin resistance; OSA: Obstructive sleep apnoea; DLP: Dyslipidemia; HFS: Hepamet fibrosis score; NFS: Non-alcoholic fatty liver disease fibrosis score; FIB-4: Fibrosis-4 index; APRI: Aspartate aminotransferase to platelet ratio index; AF: Advanced fibrosis; TE: Transient elastography; MRE: Magnetic resonance elastography; BMI: Body mass index; ALT: Alanine aminotransferase.
- Citation: Campos-Murguía A, Ruiz-Margáin A, González-Regueiro JA, Macías-Rodríguez RU. Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol 2020; 26(39): 5919-5943
- URL: https://www.wjgnet.com/1007-9327/full/v26/i39/5919.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i39.5919